Of 135 patients with advanced pancreatic cancer (stages III and IV) eligible for systemic treatment, 76 (56%) were treated with FOLFIRINOX, 35 (25%) were treated with gemcitabine-based therapies, and one BRCA2 mutated patient received olaparib. Here, BRCA2 is linked to familial pancreatic carcinoma.